Rising Kawasaki disease incidence in New Zealand: analysis of national population incidence and outcomes 2000-2017.


Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
11 2023
Historique:
received: 05 04 2023
accepted: 29 06 2023
medline: 2 11 2023
pubmed: 9 8 2023
entrez: 8 8 2023
Statut: ppublish

Résumé

The recent epidemiology of Kawasaki disease (KD) in New Zealand (NZ) is unknown. Our aim was to describe the incidence, seasonal variation, long-term outcomes and mortality for KD in NZ. Retrospective national database analysis. New Zealand. First hospitalisation and deaths diagnosed with KD. Data were extracted for all hospital admissions in NZ coded as KD (International Classification of Diseases (ICD)-9 and ICD-10) from the National Minimum Dataset 1 January 2000 to 31 December 2017. Age, sex, ethnicity and associated diagnoses were available to review. Intervention rates for immunoglobulin administration were also analysed. Over the study period, there were 1008 children with initial hospitalisation for KD. The mean age was 39.8 months (SD 37) and 592 (59%) were boys. The annual incidence rate of KD has increased from 12.2 to 19.5 per 100 000 children <5 years old (0.46 case increase per year; 95% CI 0.09 to 0.83). Children of Asian and Pacific Island ethnicities had the highest incidence (51.2 and 26.1/100 000, respectively). The highest growth in incidence was among East Asian children. The case mortality rate was low (12 of 1008, 1.2%); however, Māori were over-represented (6 of 12 deaths). There is evidence of increasing KD hospitalisation in NZ, similar to recent studies from Northeast Asia and Australia. KD incidence data were available for retrospective review from a national database, but data on complications and outcomes were incomplete. Notification for KD and an active national surveillance system are recommended to improve care. Future work should focus on factors contributing to poorer outcomes in Māori.

Identifiants

pubmed: 37553209
pii: archdischild-2023-325667
doi: 10.1136/archdischild-2023-325667
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

916-921

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Paul Gee (P)

Emergency Medicine, Christchurch Hospital Te Whata Ora, Christchurch, New Zealand paul.gee@cdhb.health.nz.
Department of Surgery and Critical Care, University of Otago, Christchurch School of Medicine, Christchurch, New Zealand.

David Burgner (D)

Infection and Immunity Theme, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.

Waverley Gee (W)

Department of Radiology, Auckland City Hospital, Auckland, New Zealand.

Angela Forbes (A)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Christopher M A Frampton (CMA)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Andrew McCombie (A)

Department of Surgery and Critical Care, University of Otago, Christchurch School of Medicine, Christchurch, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH